Abstract
Drug hypersensitivity (DH) is a growing problem worldwide. Although the exact mechanism is not well understood, it is considered immune-mediated. Drug hypersensitivity reactions are primarily classified into immediate or delayed type reactions and their presentation range from mild skin reactions [e.g., maculopapular exanthema (MPE) and urticaria] to severe life-threatening systemic reactions, such as drug reactions with eosinophilia and systemic symptoms (DRESS), Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP) and anaphylaxis. There are four postulated models to explain the interaction between drugs, human leukocyte antigens (HLA), and T cell receptors (TCR): (1) apten theory, (2) p–i concept, (3) altered peptide repertoire model, and the (4) altered T cell receptor (TCR) repertoire. Current pharmacogenomic studies have shown that pre-prescription screening of HLAs and drug-metabolizing enzymes variants may prevent severe cutaneous adverse reactions. The basic understanding of the mechanisms of DH would serve as a platform for future approaches to prevent and treat such diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- ADR:
-
Adverse drug reactions
- APC:
-
Antigen-presenting cells
- CBZ:
-
Carbamazepine
- CCL:
-
Chemokine (C–C motif) ligand
- CTL:
-
Cytotoxic T lymphocytes
- CXCL8 :
-
Chemotactic chemokine (C–X–C motif) ligand 8
- CYP2C:
-
Cytochrome P450 2C
- DH:
-
Drug hypersensitivity
- DRESS:
-
Drug reaction with eosinophilia and systemic symptoms
- FADD:
-
Fas-associated death domain
- GM-CSF:
-
Granulocyte–macrophage colony-stimulating factor
- HLA:
-
Human leukocyte antigen
- IFN:
-
Interferon
- IL:
-
Interleukin
- LTG:
-
Lamotrigine
- MCP:
-
Monocyte chemotactic protein
- MPE:
-
Mild maculopapular exanthema
- NK:
-
Nature killer
- NSAIDs:
-
Nonsteroidal anti-inflammatory drugs
- OXC:
-
Oxcarbazepine
- OXP:
-
Oxypurinol
- PHT:
-
Phenytoin
- RANTES:
-
Regulated upon activation, normal T-cell expressed, and secreted
- SAPLIP:
-
Saposin-like protein
- SCAR:
-
Severe cutaneous adverse reactions
- sFASL:
-
Soluble Fas ligand
- SJS:
-
Stevens–Johnson syndrome
- TCR:
-
T-cell receptors
- TEN:
-
Toxic epidermal necrolysis
- TNF-α:
-
Tumor necrosis factor-α
References
Abe R, et al. Toxic epidermal necrolysis and Stevens–Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003;162(5):1515–20.
Abe R, et al. Granulysin as a marker for early diagnosis of the Stevens–Johnson syndrome. Ann Intern Med. 2009;151(7):514–5.
Belhadjali H, et al. Mercury-induced acute generalized exanthematous pustulosis misdiagnosed as a drug-related case. Contact Dermat. 2008;59(1):52–4.
Blanca-Lopez N, et al. Immediate hypersensitivity reactions to ibuprofen and other arylpropionic acid derivatives. Allergy. 2016;71(7):1048–56.
Bots M, Medema JP. Granzymes at a glance. J Cell Sci. 2006;119(Pt 24):5011–4.
Brockow K, et al. Skin test concentrations for systemically administered drugs—an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702–12.
Canto MG, et al. Selective immediate hypersensitivity reactions to NSAIDs. Curr Opin Allergy Clin Immunol. 2009;9(4):293–7.
Caproni M, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens–Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol. 2006;155(4):722–8.
Chang CC, et al. Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. Pharmacogenom J. 2017;17(2):170–3.
Chantarangsu S, et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genom. 2009;19(2):139–46.
Chavez-Galan L, et al. Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol. 2009;6(1):15–25.
Chen YC, et al. Human herpes virus reactivations and dynamic cytokine profiles in patients with cutaneous adverse drug reactions—a prospective comparative study. Allergy. 2015;70(5):568–75.
Chen CB, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology. 2017;88(1):78–86.
Cheung YK, et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013;54(7):1307–14.
Choi JH, et al. Association of TNF-alpha promoter polymorphisms with aspirin-induced urticaria. J Clin Pharm Ther. 2009;34(2):231–8.
Choi MJ, et al. Clinicopathologic manifestations of 36 korean patients with acute generalized exanthematous pustulosis: a case series and review of the literature. Ann Dermatol. 2010;22(2):163–9.
Choquet-Kastylevsky G, et al. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol. 1998;139(6):1026–32.
Chung WH, Hung SI. Recent advances in the genetics and immunology of Stevens–Johnson syndrome and toxic epidermal necrosis. J Dermatol Sci. 2012;66(3):190–6.
Chung WH, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature. 2004;428(6982):486.
Chung WH, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens–Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343–50.
Chung WH, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014;312(5):525–34.
Chung WH, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015a;74(12):2157–64.
Chung WH, et al. Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions. J Investig Dermatol. 2015b;135(9):2237–48.
Ciccacci C, et al. Association between CYP2B6 polymorphisms and nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur J Clin Pharmacol. 2013;69(11):1909–16.
Cornejo-Garcia JA, et al. Genetic variants of the arachidonic acid pathway in non-steroidal anti-inflammatory drug-induced acute urticaria. Clin Exp Allergy. 2012;42(12):1772–81.
Correia O, et al. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol. 2002;47(1):58–62.
Deng A, et al. Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator. J Immunol. 2005;174(9):5243–8.
Dona I, et al. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs. Curr Pharm Des. 2016;22(45):6784–802.
Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9(10):1543–6.
Finkelman FD, Khodoun MV, Strait R. Human IgE-independent systemic anaphylaxis. J Allergy Clin Immunol. 2016;137(6):1674–80.
Fujiyama T, et al. Increased frequencies of Th17 cells in drug eruptions. J Dermatol Sci. 2014;73(1):85–8.
Gatanaga H, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS. 2007;21(2):264–5.
Genin E, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenom J. 2014;14(3):281–8.
Gueant JL, et al. HLA-DRA variants predict penicillin allergy in genome-wide fine-map** genoty**. J Allergy Clin Immunol. 2015;135(1):253–9.
Hashizume H, Fujiyama T, Tokura Y. Reciprocal contribution of Th17 and regulatory T cells in severe drug allergy. J Dermatol Sci. 2016;81(2):131–4.
Hetherington S, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121–2.
Hung SI, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102(11):4134–9.
Hung SI, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genom. 2006;16(4):297–306.
Hung SI, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010;11(3):349–56.
Ikeda H, et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia. 2010;51(2):297–300.
Illing PT, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012;486(7404):554–8.
Johansson SG, et al. A revised nomenclature for allergy. An EAACI position statement f–rom the EAACI nomenclature task force. Allergy. 2001;56(9):813–24.
Kabashima R, et al. Increased circulating Th17 frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis. J Eur Acad Dermatol Venereol. 2011;25(4):485–8.
Kaniwa N, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010;51(12):2461–5.
Kazeem GR, et al. High-resolution HLA genoty** and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genom. 2009;19(9):661–5.
Kim SH, et al. Genetic mechanism of aspirin-induced urticaria/angioedema. Curr Opin Allergy Clin Immunol. 2006;6(4):266–70.
Kim SH, et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens–Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics. 2010;11(6):879–84.
Kim SH, Lee KW, Song WJ, et al. Carbamazepine-induced msevere cutaneous reactions and HLA genotypes in Korea. Epilepsy Res. 2011;97:190–7.
Kim SH, et al. A functional promoter polymorphism of the human IL18 gene is associated with aspirin-induced urticaria. Br J Dermatol. 2011a;165(5):976–84.
Kim SH, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 2011b;97(1–2):190–7.
Kim SK, et al. Upregulated RIP3 expression potentiates MLKL phosphorylation-mediated programmed necrosis in toxic epidermal necrolysis. J Investig Dermatol. 2015;135(8):2021–30.
Kim D, et al. Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report. Nat Med. 2020;26(2):236–43.
Kishimoto TK, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008;358(23):2457–67.
Konvinse KC, et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol. 2019;144(1):183–92.
Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225–74.
Laroche D, et al. Anaphylactoid and anaphylactic reactions to iodinated contrast material. Allergy. 1999;54(Suppl 58):13–6.
Littera R, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS. 2006;20(12):1621–6.
Locharernkul C, et al. Carbamazepine and phenytoin induced Stevens–Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49(12):2087–91.
Lonjou C, et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genom. 2008;18(2):99–107.
Mallal S, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727–32.
Mallal S, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568–79.
Martin AM, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS. 2005;19(1):97–9.
McCormack M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134–43.
Meier-Schiesser B, et al. Culprit drugs induce specific IL-36 overexpression in acute generalized exanthematous pustulosis. J Investig Dermatol. 2019;139(4):848–58.
Mockenhaupt M, et al. HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans. Allergy. 2019;74(11):2227–30.
Montanez MI, et al. Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis. Front Immunol. 2017;8:614.
Moon TC, Befus AD, Kulka M. Mast cell mediators: their differential release and the secretory pathways involved. Front Immunol. 2014;5:569.
Morel E, et al. CD94/NKG2C is a killer effector molecule in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol. 2010;125(3):703–10.
Munoz-Cano R, et al. Mechanisms of anaphylaxis beyond IgE. J Investig Allergol Clin Immunol. 2016;26(2):73–82.
Naisbitt DJ, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol. 2003;63(3):732–41.
Nassif A, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Investig Dermatol. 2002;118(4):728–33.
Nassif A, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Investig Dermatol. 2004;123(5):850–5.
Navarini AA, et al. Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Investig Dermatol. 2013;133(7):1904–7.
Ng CY, et al. Impact of the HLA-B(*)58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions. J Investig Dermatol. 2016;136(7):1373–81.
Olteanu C, et al. The 10th international congress on cutaneous adverse drug reactions, Shimane, Japan, 2018: focus on new discoveries. Drug Saf. 2019;42(6):797–801.
Ostrov DA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA. 2012;109(25):9959–64.
Oussalah A, et al. Genetic variants associated with drugs-induced immediate hypersensitivity reactions: a PRISMA-compliant systematic review. Allergy. 2016;71(4):443–62.
Ozeki T, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20(5):1034–41.
Pacor ML, et al. Relationship between human leucocyte antigen class I and class II and chronic idiopathic urticaria associated with aspirin and/or NSAIDs hypersensitivity. Mediat Inflamm. 2006;2006(5):62489.
Padovan E, et al. Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy. Eur J Immunol. 1997;27(6):1303–7.
Pan RY, et al. Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Nat Commun. 2019;10(1):3569.
Paquet P, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol. 1994;130(5):605–8.
Paquet P, et al. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol. 2000;22(5):413–7.
Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p–i concept. Curr Opin Allergy Clin Immunol. 2002;2(4):301–5.
Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139(8):683–93.
Pinkoski MJ, et al. Granzyme B-mediated apoptosis proceeds predominantly through a Bcl-2-inhibitable mitochondrial pathway. J Biol Chem. 2001;276(15):12060–7.
Qiao HL, Yang J, Zhang YW. Relationships between specific serum IgE, cytokines and polymorphisms in the IL-4, IL-4Ralpha in patients with penicillins allergy. Allergy. 2005;60(8):1053–9.
Quiralte J, et al. Association of HLA-DR11 with the anaphylactoid reaction caused by nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol. 1999;103(4):685–9.
Redwood AJ, et al. Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results. J Allergy Clin Immunol. 2019;144(5):1413–6.
Rive CM, Bourke J, Phillips EJ. Testing for drug hypersensitivity syndromes. Clin Biochem Rev. 2013;34(1):15–38.
Romano A, et al. Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann Allergy Asthma Immunol. 1998;80(5):433–7.
Saag M, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46(7):1111–8.
Saito N, et al. An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions. Sci Transl Med. 2014;6(245):245ra95.
Schaerli P, et al. Characterization of human T cells that regulate neutrophilic skin inflammation. J Immunol. 2004;173(3):2151–8.
Schnyder B, Pichler WJ. Mechanisms of drug-induced allergy. Mayo Clin Proc. 2009;84(3):268–72.
Shepherd FA, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32.
Shi YW, et al. Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. Basic Clin Pharmacol Toxicol. 2011;109(1):42–6.
Somkrua R, et al. Association of HLA-B*5801 allele and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet. 2011;12:118.
Su SC, et al. Interleukin-15 is associated with severity and mortality in Stevens–Johnson syndrome/toxic epidermal necrolysis. J Investig Dermatol. 2017;137(5):1065–73.
Subramanian H, Gupta K, Ali H. Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases. J Allergy Clin Immunol. 2016;138(3):700–10.
Tangamornsuksan W, Lohitnavy M. Association between HLA-B*5901 and methazolamide-induced Stevens–Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. Pharmacogenom J. 2019;19(3):286–94.
Tangamornsuksan W, et al. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(9):1025–32.
Tanno LK, et al. The absence of CYP3A5*3 is a protective factor to anticonvulsants hypersensitivity reactions: a case-control study in Brazilian subjects. PLoS One. 2015;10(8):e0136141.
Tapia B, et al. Involvement of CCL27–CCR10 interactions in drug-induced cutaneous reactions. J Allergy Clin Immunol. 2004;114(2):335–40.
Tassaneeyakul W, et al. Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenet Genom. 2016;26(5):225–34.
Teraki Y, Fukuda T. Skin-homing IL-13-producing T cells expand in the circulation of patients with drug rash with eosinophilia and systemic symptoms. Dermatology. 2017;233(2–3):242–9.
Tsai YG, et al. Increased type 2 innate lymphoid cells in patients with drug reaction with eosinophilia and systemic symptoms syndrome. J Investig Dermatol. 2019;139(8):1722–31.
Valeyrie-Allanore L, Sassolas B, Roujeau JC. Drug-induced skin, nail and hair disorders. Drug Saf. 2007;30(11):1011–30.
Viard I, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490–3.
Viard-Leveugle I, et al. TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Investig Dermatol. 2013;133(2):489–98.
Watkins S, Pichler WJ. Sulfamethoxazole induces a switch mechanism in T cell receptors containing TCRVβ20-1, altering pHLA recognition. PLoS One. 2013;8(10):e76211.
Wedi B. Definitions and mechanisms of drug hypersensitivity. Expert Rev Clin Pharmacol. 2010;3(4):539–51.
Wei CY, et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens–Johnson syndrome. J Allergy Clin Immunol. 2012;129(6):1562–9.
**ong H, et al. Comprehensive assessment of T cell receptor beta repertoire in Stevens–Johnson syndrome/toxic epidermal necrolysis patients using high-throughput sequencing. Mol Immunol. 2019;106:170–7.
Yang J, Qiao HL, Dong ZM. Polymorphisms of IL-13 and IL-4-IL-13-SNPs in patients with penicillin allergies. Eur J Clin Pharmacol. 2005;61(11):803–9.
Yang J, et al. HLA-DRB genotype and specific IgE responses in patients with allergies to penicillins. Chin Med J. 2006;119(6):458–66.
Yang CW, et al. The interferon-gamma-induced protein 10/CXCR3 axis is associated with human herpesvirus-6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms. Br J Dermatol. 2020;183(5):909–19.
Zhang FR, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 2013;369(17):1620–8.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Chang, CJ., Chen, CB., Chung, WH. (2022). Mechanisms of Drug Hypersensitivity. In: Lee, H.Y., Creamer, D. (eds) Drug Eruptions. Updates in Clinical Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-031-09388-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-031-09388-3_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-09387-6
Online ISBN: 978-3-031-09388-3
eBook Packages: MedicineMedicine (R0)